Schering's Specialty Focus Includes Alzheimer's, Oncology
This article was originally published in Pharmaceutical Approvals Monthly
Schering-Plough's specialty drug pipeline - part of big pharma's overall efforts to hedge against the dwindling primary care market - includes several potential first-in-class or best-in-class compounds addressing oncology, Alzheimer's disease, Parkinson's disease and other specialty areas
You may also be interested in...
Schering-Plough is in a strong financial position for deal-making as it moves into the "build the base" phase of its restructuring initiative, where the firm is actively looking for acquisitions to bolster its R&D portfolio, CEO Fred Hassan said during the company's third quarter earnings call Oct. 20
A Phase III trial testing dapagliflozin in chronic kidney disease patients with and without diabetes was stopped early following a recommendation from an independent data monitoring committee.
The company is the latest big pharma to announce clinical trial delays due to the COVID-19 pandemic and has postponed an R&D day, but it also delivered the message that supply and commercial operations appear on track.